Estimation of the efficiency of using interferon inducer in children with Epstein-Barr viral infection

The aim of the research. To evaluate the effectiveness of synthetic low-molecular interferon inducers in children with Epstein-Barr viral infection. Material and methods. The study included 68 children aged 7 to 17 years with primary Epstein-Barr viral infection: 38 children in the main group received basic therapy against the primary form of Epstein-Barr viral infection in age-specific dosages in combination with a synthetic low-molecular interferon inducer; 30 children of the control group received the conventional basic therapy with age-specific dosages. Results. It has been established that clinical manifestation of Epstein-Barr viral infection is based on immunopathological inflammation mediated by the factors of cellular immunity. As a result of the therapy, 78.95 % of children in the main group had a normal rate of functional recovery of the liver. In the control group, however, the recovery was delayed in 60.00 % of children: rapid recovery was only noted in the main group. Administration of synthetic lowmolecular weight interferon inducers in addition to basic symptomatic therapy facilitated the reduction of intoxication symptoms duration by 4.7±1.9 days (p < 0.05) and the duration of the icteric period by 5.3±0.9 days (p < 0.05), as well as 5.1±1.3 days earlier normalisation of liver size (p < 0.05). Conclusion. Thus, the use of synthetic low molecular weight interferon inducers in combination with basic therapy against the primary form of Epstein-Barr viral infection in children contributes to a faster restoration of the functional state of the liver. The conducted clinical and biochemical studies indicate high efficiency of synthetic low molecular weight interferon inducers in the complex therapy of Epstein-Barr viral infection in children.